Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sartorius Stedim Biotech S.A. (DIM.PA)
EUR189.80
+1.30 (+0.69%)
FR PAR Healthcare Medical - Instruments & Supplies
Address
Zone Industrielle Les Paluds 13781
Aubagne, FR
Aubagne, FR
CEO
Rene Faber
Website
sartorius.com
IPO
2000-01-03
ISIN FR0013154002
Also trades on
Euronext Paris · DIM.PA (EUR)
Other OTC · SDMHF (USD)
Other OTC · SRTOY (USD)
Description
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR189.80
+1.30 (+0.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
94.7K
Beta
1.13
Float Shares
27.69M
Free Float %
28.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.95% | +3.79% | +13.66% | -2.73% | -14.09% | -15.19% | -8.20% | -28.39% | -49.75% | +212.24% | +118,633.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
189.80
DCF (Unlevered)
28.08
-85.2%
DCF (Levered)
25.02
-86.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.54
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+6.7% Q1'26: +2.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+50.8% ★ Q1'26: +3.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.9% Q1'26: +14.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.5% ★ Q1'26: +18.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+6.1% ★ Q1'26: +6.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.5% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.17× Q1'26: 2.91× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 9 EPS Ana. |
Dec 2027 13 Rev. Ana. 10 EPS Ana. |
Dec 2028 12 Rev. Ana. 8 EPS Ana. |
Dec 2029 11 Rev. Ana. 6 EPS Ana. |
Dec 2030 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
39.33M
est.
|
41.28M
est.
|
42.28M
est.
|
65.72M
est.
|
484.30M
est: 86.55M (+459.6%)
|
521.05M
est: 93.16M (+459.3%)
|
268.84M
est: 363.66M (-26.1%)
|
368.00M
est: 381.50M (-3.5%)
|
401.23M
est: 407.47M (-1.5%)
|
432.95M
est: 436.22M (-0.8%)
|
477.30M
est: 482.78M (-1.1%)
|
543.96M
est: 556.68M (-2.3%)
|
588.38M
est: 603.42M (-2.5%)
|
683.52M
est: 675.56M (+1.2%)
|
884.33M
est: 887.01M (-0.3%)
|
1.05B
est: 1.05B (+0.4%)
|
1.08B
est: 1.09B (-0.5%)
|
1.21B
est: 1.21B (+0.0%)
|
1.44B
est: 1.44B (+0.3%)
|
1.91B
est: 1.88B (+1.5%)
|
2.89B
est: 2.87B (+0.5%)
|
3.49B
est: 3.50B (-0.3%)
|
2.78B
est: 2.75B (+1.0%)
|
2.78B
est: 2.76B (+0.6%)
|
2.97B
est: 2.97B (-0.2%)
|
3.17B
3.14B – 3.20B
+6.6% YoY
|
3.50B
3.45B – 3.58B
+10.5% YoY
|
3.88B
3.88B – 3.89B
+10.9% YoY
|
4.30B
4.25B – 4.37B
+10.8% YoY
|
4.84B
4.78B – 4.92B
+12.5% YoY
|
| EBITDA |
6.56M
est.
|
8.19M
est.
|
6.55M
est.
|
8.55M
est.
|
53.82M
est: 16.33M (+229.6%)
|
65.32M
est: 17.17M (+280.3%)
|
29.27M
est: 63.63M (-54.0%)
|
50.00M
est: 24.31M (+105.7%)
|
71.65M
est: 45.07M (+59.0%)
|
83.31M
est: 68.62M (+21.4%)
|
91.10M
est: 86.55M (+5.3%)
|
113.36M
est: 102.97M (+10.1%)
|
129.05M
est: 114.36M (+12.8%)
|
152.85M
est: 134.12M (+14.0%)
|
225.91M
est: 173.74M (+30.0%)
|
270.91M
est: 241.37M (+12.2%)
|
279.59M
est: 260.90M (+7.2%)
|
360.07M
est: 295.49M (+21.9%)
|
410.74M
est: 400.77M (+2.5%)
|
569.20M
est: 486.12M (+17.1%)
|
811.96M
est: 565.23M (+43.7%)
|
1.33B
est: 627.40M (+112.1%)
|
755.70M
est: 806.44M (-6.3%)
|
670.50M
est: 826.98M (-18.9%)
|
867.10M
est: 873.26M (-0.7%)
|
931.13M
920.44M – 940.32M
+6.6% YoY
|
1.03B
1.01B – 1.05B
+10.5% YoY
|
1.14B
1.14B – 1.14B
+10.9% YoY
|
1.26B
1.25B – 1.28B
+10.8% YoY
|
1.42B
1.40B – 1.44B
+12.5% YoY
|
| EBIT |
5.11M
est.
|
5.67M
est.
|
4.71M
est.
|
5.13M
est.
|
35.33M
est: 8.56M (+312.8%)
|
46.10M
est: 10.06M (+358.1%)
|
14.01M
est: 45.28M (-69.1%)
|
34.34M
est: 14.95M (+129.7%)
|
48.96M
est: 35.99M (+36.0%)
|
60.33M
est: 52.03M (+15.9%)
|
70.07M
est: 66.04M (+6.1%)
|
87.49M
est: 82.19M (+6.4%)
|
99.27M
est: 94.52M (+5.0%)
|
111.17M
est: 113.41M (-2.0%)
|
173.87M
est: 160.84M (+8.1%)
|
217.39M
est: 217.01M (+0.2%)
|
225.03M
est: 234.17M (-3.9%)
|
288.54M
est: 248.01M (+16.3%)
|
322.03M
est: 356.39M (-9.6%)
|
467.51M
est: 423.70M (+10.3%)
|
670.40M
est: 492.65M (+36.1%)
|
1.15B
est: 546.83M (+110.1%)
|
518.90M
est: 585.38M (-11.4%)
|
368.80M
est: 591.20M (-37.6%)
|
549.00M
est: 633.88M (-13.4%)
|
675.89M
668.13M – 682.56M
+6.6% YoY
|
746.62M
735.12M – 762.43M
+10.5% YoY
|
827.86M
827.76M – 827.96M
+10.9% YoY
|
917.27M
904.86M – 931.77M
+10.8% YoY
|
1.03B
1.02B – 1.05B
+12.5% YoY
|
| Net Income |
4.50M
est.
|
5.04M
est.
|
3.58M
est.
|
4.82M
est.
|
22.03M
est: 6.72M (+228.0%)
|
29.02M
est: 7.55M (+284.5%)
|
4.74M
est: 26.15M (-81.9%)
|
13.10M
est: 5.06M (+159.2%)
|
29.09M
est: 13.99M (+107.9%)
|
38.51M
est: 31.15M (+23.6%)
|
43.19M
est: 42.45M (+1.7%)
|
56.76M
est: 49.76M (+14.1%)
|
66.28M
est: 61.57M (+7.6%)
|
72.47M
est: 74.23M (-2.4%)
|
118.00M
est: 96.84M (+21.8%)
|
153.68M
est: 138.77M (+10.7%)
|
161.09M
est: 159.29M (+1.1%)
|
208.05M
est: 180.20M (+15.5%)
|
234.57M
est: 246.97M (-5.0%)
|
335.93M
est: 299.34M (+12.2%)
|
414.40M
est: 348.05M (+19.1%)
|
876.10M
est: 386.33M (+126.8%)
|
309.70M
est: 175.27M (+76.7%)
|
175.10M
est: 316.25M (-44.6%)
|
265.60M
est: 428.02M (-37.9%)
|
484.35M
446.48M – 522.21M
+13.2% YoY
|
588.44M
538.84M – 638.05M
+21.5% YoY
|
709.84M
611.08M – 808.60M
+20.6% YoY
|
818.44M
804.04M – 835.26M
+15.3% YoY
|
985.65M
968.30M – 1.01B
+20.4% YoY
|
| SGA |
22.37M
est.
|
22.78M
est.
|
24.48M
est.
|
38.71M
est.
|
-82.48M
est: 41.74M (-297.6%)
|
-89.30M
est: 19.91M (-548.5%)
|
75.92M
est: 75.73M (+0.3%)
|
111.23M
est: 81.64M (+36.2%)
|
108.93M
est: 118.77M (-8.3%)
|
119.68M
est: 116.58M (+2.7%)
|
126.46M
est: 131.98M (-4.2%)
|
142.87M
est: 146.03M (-2.2%)
|
158.70M
est: 155.66M (+2.0%)
|
182.95M
est: 176.67M (+3.6%)
|
216.10M
est: 244.84M (-11.7%)
|
243.07M
est: 255.17M (-4.7%)
|
256.93M
est: 251.27M (+2.3%)
|
282.21M
est: 287.44M (-1.8%)
|
316.81M
est: 336.86M (-6.0%)
|
391.54M
est: 407.70M (-4.0%)
|
531.76M
est: 474.05M (+12.2%)
|
601.20M
est: 526.18M (+14.3%)
|
616.20M
est: 445.88M (+38.2%)
|
648.50M
est: 450.32M (+44.0%)
|
—
est: 482.83M (-100.0%)
|
514.83M
508.92M – 519.91M
+6.6% YoY
|
568.70M
559.94M – 580.75M
+10.5% YoY
|
630.58M
630.51M – 630.66M
+10.9% YoY
|
698.69M
689.23M – 709.73M
+10.8% YoY
|
785.95M
775.31M – 798.37M
+12.5% YoY
|
| EPS |
0.12
est.
|
0.08
est.
|
0.09
est.
|
0.11
est.
|
0.22
est: 0.16 (+39.2%)
|
0.28
est: 0.18 (+52.8%)
|
0.05
est: 0.25 (-81.5%)
|
0.13
est: 0.21 (-38.1%)
|
0.28
est: 0.30 (-6.9%)
|
0.40
est: 0.40 (+0.8%)
|
0.47
est: 0.52 (-9.2%)
|
0.62
est: 0.61 (+0.9%)
|
0.72
est: 0.77 (-6.8%)
|
0.79
est: 0.90 (-12.6%)
|
1.28
est: 1.39 (-8.2%)
|
1.67
est: 1.80 (-7.4%)
|
1.75
est: 1.81 (-3.4%)
|
2.26
est: 2.24 (+0.7%)
|
2.54
est: 2.87 (-11.5%)
|
3.64
est: 3.96 (-8.1%)
|
4.50
est: 7.08 (-36.4%)
|
9.51
est: 8.69 (+9.4%)
|
3.36
est: 1.80 (+86.8%)
|
1.81
est: 3.25 (-44.2%)
|
2.73
est: 4.39 (-37.8%)
|
5.10
4.59 – 5.37
+16.1% YoY
|
6.05
5.54 – 6.56
+18.6% YoY
|
7.18
6.28 – 8.31
+18.7% YoY
|
8.41
8.26 – 8.58
+17.2% YoY
|
10.13
9.95 – 10.34
+20.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
275.15M
OE per share TTM
2.82
Owner's Yield
1.59%
Maintenance CapEx ratio
69.59%
Maint CapEx / Avg PPE
49.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 265 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | T. Rowe Price Global Equity ETF TGLB | 2.06% | 483.3K | 0.46% |
| 2 | Fidelity Disruptive Medicine ETF FMED | 1.89% | 875.3K | 0.50% |
| 3 | VanEck Morningstar International Moat ETF MOTI | 1.49% | 1.05M | 0.58% |
| 4 | VanEck Morningstar Global Wide Moat UCITS ETF GOAT.L | 1.07% | 1.83M | 0.52% |
| 5 | VanEck Morningstar Global Wide Moat ETF MOTG | 1.07% | 187.3K | 0.52% |
| 6 | iShares EURO STOXX Mid UCITS ETF DJMC.L | 0.65% | 4.11M | 0.40% |
| 7 | Goldman Sachs Future Health Care Equity ETF GDOC | 0.51% | 97.8K | 0.75% |
| 8 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.38% | 51.2K | 0.20% |
| 9 | State Street SPDR MSCI Europe Health Care UCITS ETF HLTH.L | 0.33% | 2.28M | 0.18% |
| 10 | iShares MSCI Europe Health Care Sector UCITS ETF ESIH.L | 0.33% | 3.36M | 0.18% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
55.1K
Shares Outstanding
97.30M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rene Faber | Chief Executive Officer & DIrector | 1M | — |
| Petra Muller | Head of Investor Relations | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DIM.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
